JP7602857B2 - 加齢性肥満改善剤及び脂肪分解力改善剤 - Google Patents
加齢性肥満改善剤及び脂肪分解力改善剤 Download PDFInfo
- Publication number
- JP7602857B2 JP7602857B2 JP2018104528A JP2018104528A JP7602857B2 JP 7602857 B2 JP7602857 B2 JP 7602857B2 JP 2018104528 A JP2018104528 A JP 2018104528A JP 2018104528 A JP2018104528 A JP 2018104528A JP 7602857 B2 JP7602857 B2 JP 7602857B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- age
- extract
- bofutsushosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008589 Obesity Diseases 0.000 title claims description 74
- 235000020824 obesity Nutrition 0.000 title claims description 74
- 230000004130 lipolysis Effects 0.000 title claims description 50
- 239000000284 extract Substances 0.000 claims description 112
- 239000009520 bofu-tsusho-san Substances 0.000 claims description 109
- 238000012360 testing method Methods 0.000 claims description 73
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 150000002632 lipids Chemical class 0.000 claims description 50
- 210000000577 adipose tissue Anatomy 0.000 claims description 45
- 230000002366 lipolytic effect Effects 0.000 claims description 31
- 238000000354 decomposition reaction Methods 0.000 claims description 30
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 28
- 229960002748 norepinephrine Drugs 0.000 claims description 28
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 28
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 25
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 25
- 230000000638 stimulation Effects 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 17
- 235000021588 free fatty acids Nutrition 0.000 claims description 16
- 241000411851 herbal medicine Species 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 12
- 229940098773 bovine serum albumin Drugs 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 206010033675 panniculitis Diseases 0.000 claims description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 72
- 239000000843 powder Substances 0.000 description 48
- 238000004519 manufacturing process Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 230000029142 excretion Effects 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 235000006886 Zingiber officinale Nutrition 0.000 description 23
- 235000008397 ginger Nutrition 0.000 description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 241000234314 Zingiber Species 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 239000003925 fat Substances 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 17
- 230000002503 metabolic effect Effects 0.000 description 16
- 210000003608 fece Anatomy 0.000 description 15
- 239000000654 additive Substances 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 210000001596 intra-abdominal fat Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 235000009200 high fat diet Nutrition 0.000 description 12
- 241000207929 Scutellaria Species 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 230000006872 improvement Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 235000008216 herbs Nutrition 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000012676 herbal extract Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 241000218671 Ephedra Species 0.000 description 5
- 241000555712 Forsythia Species 0.000 description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 229950008138 carmellose Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 238000013116 obese mouse model Methods 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- 241000219475 Bougainvillea Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000725101 Clea Species 0.000 description 4
- 241000212948 Cnidium Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000006751 Platycodon Nutrition 0.000 description 4
- 244000274050 Platycodon grandiflorum Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229930189914 platycodon Natural products 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241000132012 Atractylodes Species 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 239000004129 EU approved improving agent Substances 0.000 description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 3
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013585 weight reducing agent Substances 0.000 description 3
- 241000544270 Angelica acutiloba Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- HFCSXCKLARAMIQ-UHFFFAOYSA-L disodium;sulfate;hydrate Chemical compound O.[Na+].[Na+].[O-]S([O-])(=O)=O HFCSXCKLARAMIQ-UHFFFAOYSA-L 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 231100000272 reduced body weight Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 235000018062 Boswellia Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 101000845012 Macrovipera lebetina Disintegrin lebein-1-alpha Proteins 0.000 description 1
- 101000845007 Macrovipera lebetina Disintegrin lebein-1-beta Proteins 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- ZZNMWGVMOBOREI-VQTJNVASSA-N chembl464952 Chemical compound C1([C@H]2OC=3C4=C(C=5C=CC(C)(C)OC=5C=3C(=O)[C@@H]2O)OC(C=C4)(C)C)=CC=CC=C1 ZZNMWGVMOBOREI-VQTJNVASSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000004691 decahydrates Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920003121 gastrosoluble polymer Polymers 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000020339 pu-erh tea Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022084727A JP2022105650A (ja) | 2017-08-10 | 2022-05-24 | 加齢性肥満改善剤及び脂肪分解力改善剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017156131 | 2017-08-10 | ||
| JP2017156131 | 2017-08-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084727A Division JP2022105650A (ja) | 2017-08-10 | 2022-05-24 | 加齢性肥満改善剤及び脂肪分解力改善剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019034926A JP2019034926A (ja) | 2019-03-07 |
| JP7602857B2 true JP7602857B2 (ja) | 2024-12-19 |
Family
ID=65636911
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018104528A Active JP7602857B2 (ja) | 2017-08-10 | 2018-05-31 | 加齢性肥満改善剤及び脂肪分解力改善剤 |
| JP2018104527A Active JP7133982B2 (ja) | 2017-08-10 | 2018-05-31 | 錠剤組成物 |
| JP2022084726A Active JP7475393B2 (ja) | 2017-08-10 | 2022-05-24 | 錠剤組成物 |
| JP2022084727A Pending JP2022105650A (ja) | 2017-08-10 | 2022-05-24 | 加齢性肥満改善剤及び脂肪分解力改善剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018104527A Active JP7133982B2 (ja) | 2017-08-10 | 2018-05-31 | 錠剤組成物 |
| JP2022084726A Active JP7475393B2 (ja) | 2017-08-10 | 2022-05-24 | 錠剤組成物 |
| JP2022084727A Pending JP2022105650A (ja) | 2017-08-10 | 2022-05-24 | 加齢性肥満改善剤及び脂肪分解力改善剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (4) | JP7602857B2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021161117A (ja) * | 2020-03-30 | 2021-10-11 | ロート製薬株式会社 | 錠剤 |
| JP2021187801A (ja) * | 2020-06-03 | 2021-12-13 | 小林製薬株式会社 | 脂質排泄促進剤 |
| JP2023056439A (ja) * | 2021-10-07 | 2023-04-19 | ロート製薬株式会社 | 固形組成物 |
| JP2023172517A (ja) * | 2022-05-24 | 2023-12-06 | 小林製薬株式会社 | 錠剤組成物 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140064A1 (ja) | 2007-05-07 | 2008-11-20 | Bbk Bio Corporation | 生活習慣病の予防および改善のための栄養組成物 |
| JP2009196990A (ja) | 2008-01-25 | 2009-09-03 | Kobayashi Pharmaceut Co Ltd | 抗肥満用医薬組成物 |
| JP2009196972A (ja) | 2008-01-25 | 2009-09-03 | Kobayashi Pharmaceut Co Ltd | 医薬組成物 |
| JP2009242354A (ja) | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | 医薬組成物 |
| JP2013530981A (ja) | 2010-06-25 | 2013-08-01 | アストン ユニバーシティ | 脂質動員特性を有する糖タンパク質およびその治療的使用 |
| WO2016175362A1 (ko) | 2015-04-28 | 2016-11-03 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW464495B (en) * | 1996-06-12 | 2001-11-21 | Kyowa Hakko Kogyo Kk | Lipid metabolic ameliorative agent |
| US20090274781A1 (en) * | 2008-05-02 | 2009-11-05 | Asgen Pharmaceutical Co., Ltd. | Anti-obesity agent |
| JP5204587B2 (ja) * | 2008-08-20 | 2013-06-05 | 株式会社タニタ | 体組成予測装置および体組成判定装置 |
| JP6086798B2 (ja) * | 2013-04-25 | 2017-03-01 | 小林製薬株式会社 | 錠剤の製造方法 |
| JP6407545B2 (ja) * | 2014-03-28 | 2018-10-17 | 小林製薬株式会社 | 医薬組成物 |
| KR101760909B1 (ko) * | 2014-11-21 | 2017-07-24 | (주)휴온스 | 안정성이 개선된 한방 엑기스 함유 정제 조성물 및 이의 제조방법 |
| CN105362766A (zh) * | 2015-12-05 | 2016-03-02 | 黑龙江江恒医药科技有限公司 | 一种防风通圣丸及其制备方法 |
-
2018
- 2018-05-31 JP JP2018104528A patent/JP7602857B2/ja active Active
- 2018-05-31 JP JP2018104527A patent/JP7133982B2/ja active Active
-
2022
- 2022-05-24 JP JP2022084726A patent/JP7475393B2/ja active Active
- 2022-05-24 JP JP2022084727A patent/JP2022105650A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140064A1 (ja) | 2007-05-07 | 2008-11-20 | Bbk Bio Corporation | 生活習慣病の予防および改善のための栄養組成物 |
| JP2009196990A (ja) | 2008-01-25 | 2009-09-03 | Kobayashi Pharmaceut Co Ltd | 抗肥満用医薬組成物 |
| JP2009196972A (ja) | 2008-01-25 | 2009-09-03 | Kobayashi Pharmaceut Co Ltd | 医薬組成物 |
| JP2009242354A (ja) | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | 医薬組成物 |
| JP2013530981A (ja) | 2010-06-25 | 2013-08-01 | アストン ユニバーシティ | 脂質動員特性を有する糖タンパク質およびその治療的使用 |
| WO2016175362A1 (ko) | 2015-04-28 | 2016-11-03 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
Non-Patent Citations (4)
| Title |
|---|
| Ｅｎｄｏｃｒｉｎｏｌｏｇｙ，１９６３年，Ｖｏｌ．７２，Ｎｏ．４，ｐ．５２７－５４３ |
| Ｐｈａｒｍａｃｏｌｏｇｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ，Ｖｏｌｕｍｅ １７， Ｉｓｓｕｅ １０，ｐ．９３７－９４９ |
| 今日の治療薬２０１２、２０１２年、１０９２頁 |
| 漢方と最新治療、２０１３年、Ｖｏｌ．２２、Ｎｏ．３、ｐｐ．２２９－２３４ |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7133982B2 (ja) | 2022-09-09 |
| JP2022105650A (ja) | 2022-07-14 |
| JP2019034925A (ja) | 2019-03-07 |
| JP2019034926A (ja) | 2019-03-07 |
| JP7475393B2 (ja) | 2024-04-26 |
| JP2022105649A (ja) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7475393B2 (ja) | 錠剤組成物 | |
| KR20190023091A (ko) | 페릴라 추출 조성물 | |
| JP2025019286A (ja) | 防風通聖散エキス | |
| JP2024092065A (ja) | 脂質排泄促進剤 | |
| WO2021109511A1 (zh) | 一种抗疲劳的组合物及其制备方法 | |
| JP5984328B2 (ja) | 独活葛根湯エキス配合剤 | |
| CN114794478B (zh) | 一种能降低血压血脂血糖的组合物及应用 | |
| WO2016188092A1 (zh) | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的保健品中的应用及其保健品 | |
| JP2009242354A (ja) | 医薬組成物 | |
| JP7545242B2 (ja) | 肌荒れ改善剤 | |
| JP7788223B2 (ja) | 脂肪低減剤 | |
| JP7554041B2 (ja) | 四肢スリミング剤 | |
| JP7719641B2 (ja) | 便中脂質排泄促進剤 | |
| JP7554040B2 (ja) | 筋肉量低下抑制剤 | |
| JP7068803B2 (ja) | 血中脂質低減用医薬組成物 | |
| JP7385990B2 (ja) | 過眠症治療剤 | |
| JP7618484B2 (ja) | 錠剤組成物 | |
| Patil Pradeep et al. | Formulation and evaluation of orodispersible tablets of perindopril erbumine using natural superdisintegrant | |
| Pimpalkar et al. | Formulation and evaluation: nutraceutical herbal tablet | |
| JP2004262929A (ja) | α−グルコシダーゼ阻害剤 | |
| JP2019194258A (ja) | 内臓脂肪細胞分解剤 | |
| JP2021167309A (ja) | 脂肪低減剤 | |
| Asaab | Development of composition and technology of tablets with Rhodiola rosea extract | |
| JP2025004593A (ja) | 早朝尿量増加剤 | |
| JP2025004594A (ja) | 尿勢増加剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210415 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220524 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221202 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221202 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221212 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221213 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230120 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20230124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240925 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7602857 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |